AMIT BAR-OR ET AL: "The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (S23.006)", NEUROLOGY, vol. 82, 8 April 2014 (2014-04-08), page S23.006, XP055422339, (B1)

Anonymous: "Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple", , 2 June 2016 (2016-06-02), pages 1-2, XP055422006, Retrieved from the Internet: URL:http://files.shareholder.com/downloads /AMDA-KPIBN/5516781151x0x894702/8091DD52-2 A2B-4ACE-8C91-4C5E869E296A/28_Ofa Phase 3 Study Start_020616_uk.pdf [retrieved on 2017-11-06] (B1)

Bar-Or A ET AL: "The MIRROR Study: Treatment Phase Results for a Dose- Ranging Study of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis", , 29 April 2014 (2014-04-29), XP055422304, Retrieved from the Internet: URL:http://files.shareholder.com/downloads /AMDA-KPIBN/0x0x751370/7CCEAF8F-592C-4DA6- 9299-4C83D16DC1E1/AAN_April_2014_MIRROR_Pr esentation_Final.pdf [retrieved on 2017-11-07] (B1)

MILO RON: "Therapeutic strategies targeting B-cells in multiple sclerosis", AUTOIMMUNITY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 7, 9 March 2016 (2016-03-09), pages 714-718, XP029541469, ISSN: 1568-9972, DOI: 10.1016/J.AUTREV.2016.03.006 (B1)

WO-A1-2012/096924 (B1)

Per Soelberg Sorensen ET AL: "Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) - 24-week results of a phase II study", 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) & 15th Annual Conference of Rehabilitation in MS (RIMS) 13.10.2010 - 16.10.2010, 16 October 2010 (2010-10-16), XP055191485, Retrieved from the Internet: URL:http://registration.akm.ch/einsicht.ph p?XNABSTRACT_ID=118695&XNSPRACHE_ID=2&XNKO NGRESS_ID=126&XNMASKEN_ID=900 [retrieved on 2015-05-26] (B1)

R. KURRASCH ET AL: "Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics", THE JOURNAL OF RHEUMATOLOGY, vol. 40, no. 7, 1 June 2013 (2013-06-01), pages 1089-1096, XP055189667, ISSN: 0315-162X, DOI: 10.3899/jrheum.121118 (B1)

REBECCA STRAUS FARBER ET AL: "Novel Agents for Relapsing Forms of Multiple Sclerosis", ANNUAL REVIEW OF MEDICINE : SELECTED TOPICS IN THE CLINICALSCIENCES, vol. 67, no. 1, 17 September 2015 (2015-09-17), pages 309-321, XP055422052, US ISSN: 0066-4219, DOI: 10.1146/annurev-med-052814-023415 (B1)

PER S SORENSEN ET AL: "Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis; A phase 2 study", NEUROLOGY, vol. 82, 22 January 2014 (2014-01-22), pages 573-581, XP055422042, (B1)